Literature DB >> 24377075

Inclusion body myositis: a case of bilateral extremity weakness.

Luke Lam1, Stephen Scheper1, Natalia Zagorski1, Mark Chung1, Hiroji Noguchi1, Kore K Liow1.   

Abstract

Inflammatory myopathy is a common cause of bilateral muscular weakness in adults. Although not as common as polymyositis, inclusion body myositis (IBM) is a form of inflammatory myopathy characterized by chronic progressive muscle inflammation and often goes undiagnosed and untreated. IBM patients most commonly present with proximal lower extremity weakness and may have normal creatine kinase (CK) levels. A high level of clinical suspicion is required for prompt and accurate diagnosis of IBM, which is diagnosed definitively with a muscle biopsy. The patient described in this case report is a 68-year-old man who initially presented with both bilateral symmetric proximal lower extremity and distal upper extremity weakness. IBM was suspected through history, electromyography, and definitively diagnosed with muscle biopsy. The patient was subsequently initiated on prednisone therapy and physical therapy, with improvement in muscular strength after 2 months. In patients presenting with bilateral extremity weakness and normal CK level, the diagnosis of IBM should be included in the differential diagnosis and muscle biopsy performed for appropriate cases.

Entities:  

Keywords:  inclusion body myositis; inflammatory myopathy; weakness

Mesh:

Year:  2013        PMID: 24377075      PMCID: PMC3872918     

Source DB:  PubMed          Journal:  Hawaii J Med Public Health        ISSN: 2165-8242


  14 in total

1.  Inclusion body myositis in Connecticut: observations in 35 patients during an 8-year period.

Authors:  K J Felice; W A North
Journal:  Medicine (Baltimore)       Date:  2001-09       Impact factor: 1.889

2.  Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo.

Authors:  Umesh A Badrising; Marion L C Maat-Schieman; Michel D Ferrari; Aeilko H Zwinderman; Judith A M Wessels; Ferdinand C Breedveld; Pieter A van Doorn; Baziel G M van Engelen; Jessica E Hoogendijk; Chris J Höweler; Aeiko E de Jager; Frans G I Jennekens; Peter J Koehler; Marianne de Visser; Alain Viddeleer; Jan J Verschuuren; Axel R Wintzen
Journal:  Ann Neurol       Date:  2002-03       Impact factor: 10.422

3.  Inclusion body myositis: analysis of 32 cases.

Authors:  M E Sayers; S M Chou; L H Calabrese
Journal:  J Rheumatol       Date:  1992-09       Impact factor: 4.666

4.  Spectrum of inclusion body myositis.

Authors:  S P Ringel; C E Kenny; H E Neville; R Giorno; M R Carry
Journal:  Arch Neurol       Date:  1987-11

Review 5.  Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches.

Authors:  Merrilee Needham; Frank L Mastaglia
Journal:  Lancet Neurol       Date:  2007-07       Impact factor: 44.182

6.  Disease progression in sporadic inclusion body myositis: observations in 78 patients.

Authors:  A Peng; B M Koffman; J D Malley; M C Dalakas
Journal:  Neurology       Date:  2000-07-25       Impact factor: 9.910

7.  Prevalence of sporadic inclusion body myositis in Western Australia.

Authors:  B A Phillips; P J Zilko; F L Mastaglia
Journal:  Muscle Nerve       Date:  2000-06       Impact factor: 3.217

8.  Inclusion body myositis. Observations in 40 patients.

Authors:  B P Lotz; A G Engel; H Nishino; J C Stevens; W J Litchy
Journal:  Brain       Date:  1989-06       Impact factor: 13.501

Review 9.  Polymyositis and dermatomyositis.

Authors:  Marinos C Dalakas; Reinhard Hohlfeld
Journal:  Lancet       Date:  2003-09-20       Impact factor: 79.321

10.  Inclusion body myositis: clinical and histopathological features of 36 patients.

Authors:  S Beyenburg; S Zierz; F Jerusalem
Journal:  Clin Investig       Date:  1993-05
View more
  1 in total

1.  Inclusion Body Myositis Treated with Alemtuzumab.

Authors:  Juliana Sá; João Costelha; Antonio Marinho
Journal:  Eur J Case Rep Intern Med       Date:  2019-12-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.